1. Clinical & Scientific Overview
Pyridoxine Hydrochloride (Vitamin B6) (TIP-MED-000197, Reference Code [10.13]) is classified under
Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Pyridoxal-5'-Phosphate (PLP) Coenzyme for Amino Acid & Neurotransmitter Synthesis (Schedule H / OTC | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.13], p. 133): Benadon (Abbott — 40 mg), Pyridox, B-Long (100 mg SR); FDCs: Doxinate / Pregnidoxin (Doxylamine 10/20 mg + Pyridoxine 10/20 mg for Nausea & Vomiting of Pregnancy) — Strengths & Dosage Forms: Tablets: 10 mg, 20 mg, 40 mg, 50 mg, 100 mg SR; IV Injection (for Isoniazid overdose seizures)
Tablets: 10 mg, 20 mg, 40 mg, 50 mg, 100 mg SR; IV Injection (for Isoniazid overdose seizures)
3. Mechanism of Action & Pharmacodynamics
Pyridoxal-5'-Phosphate (PLP) Coenzyme for Amino Acid & Neurotransmitter Synthesis (Schedule H / OTC | NLEM 2022) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Pyridoxal-5'-Phosphate (PLP) Coenzyme for Amino Acid & Neurotransmitter Synthesis (Schedule H / OTC | NLEM 2022) for Mandatory prophylaxis and treatment of Isoniazid (INH)-induced peripheral neuropathy in all Tuberculosis patients (NTEP protocol); first-line treatment of Nausea and Vomiting of Pregnancy (NVP, alone or with Doxylamine); Pyridoxine-dependent neonatal seizures; sideroblastic anaemia.
4. Therapeutic Indications & Evidence-Supported Uses
- Mandatory prophylaxis and treatment of Isoniazid (INH)-induced peripheral neuropathy in all Tuberculosis patients (NTEP protocol)
- first-line treatment of Nausea and Vomiting of Pregnancy (NVP, alone or with Doxylamine)
- Pyridoxine-dependent neonatal seizures
- sideroblastic anaemia
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Isoniazid Neuropathy Prophylaxis (Routine TB): 10–20 mg (half of a 40 mg Benadon tab) PO OD (Use 40–50 mg OD in high-risk TB patients: diabetes, HIV, pregnancy, alcoholism, malnutrition, CKD, or Linezolid co-therapy). Established INH Neuropathy: 50–100 mg PO OD–BD. Morning Sickness (NVP): 10–25 mg PO TDS (or Doxylamine + Pyridoxine 10/10 mg 2 tabs at bedtime)
Administration & Meal Timing: Take with or after meals (for TB patients, may be taken alongside morning 4-FDC/3-FDC tablets) | Morning (Once Daily with TB medicines); Bedtime (for Doxinate in pregnancy nausea)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal & Hepatic: Safe across all CKD and hepatic stages (essential in dialysis patients due to dialytic PLP clearance)
Renal & Hepatic: Safe across all CKD and hepatic stages (essential in dialysis patients due to dialytic PLP clearance)
Renal & Hepatic: Safe across all CKD and hepatic stages (essential in dialysis patients due to dialytic PLP clearance)
7. Contraindications, Precautions & High-Risk Warnings
- PARADOXICAL HIGH-DOSE SENSORY NEUROPATHY WARNING: While 10–50 mg/day prevents neuropathy, chronic megadoses of Pyridoxine (>200–500 mg/day for months) are neurotoxic to dorsal root ganglia and CAUSE severe sensory ataxia and peripheral neuropathy! Never exceed prescribed doses
Key Clinical Precautions: Renal & Hepatic: Safe across all CKD and hepatic stages (essential in dialysis patients due to dialytic PLP clearance)
8. Adverse Effects Profile
- None at 10–100 mg/day
- Sensory ganglionopathy / severe peripheral neuropathy and ataxia if megadoses (>200–500 mg/d) are taken long-term
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL LEVODOPA INTERACTION: Pyridoxine (>=5–10 mg/day) activates peripheral aromatic L-amino acid decarboxylase and blocks plain Levodopa — HOWEVER, this interaction does NOT occur when Levodopa is co-formulated with Carbidopa or Benserazide (Syndopa / Madopar)! High-dose Pyridoxine (>80–200 mg/d) can lower serum Phenytoin and Phenobarbital levels
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Every patient taking Isoniazid (AKT-4 / Akurit-4) or Linezolid for Tuberculosis must take Benadon (Vitamin B6) daily to prevent painful foot numbness and tingling; Doxinate (Vitamin B6 + Doxylamine) is the safest first-line tablet for morning sickness in early pregnancy
- Meal & Clock Timing Instruction: Take with or after meals (for TB patients, may be taken alongside morning 4-FDC/3-FDC tablets) (Morning (Once Daily with TB medicines); Bedtime (for Doxinate in pregnancy nausea))
- Missed Dose Protocol: Take same day if remembered
- Geriatric Dispensing Pearl: Safe at 10–50 mg/day in older adults
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablets: 10 mg, 20 mg, 40 mg, 50 mg, 100 mg SR; IV Injection (for Isoniazid overdose seizures)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.13] (p. 133)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [10.6] Calcium Citrate / Calcium Citrate Malate (CCM) — Organic Acid-Independent Soluble Calcium Salt (~21–24% Elemental
- [10.9] Zinc (Zinc Sulphate Monohydrate / Zinc Acetate / Zinc Gluconate) — Essential Trace Element Cofactor (>300 Metalloenzymes: DNA/RNA Po
- [10.10] Oral Magnesium Salts (Magnesium Oxide, Citrate & Bisglycinate — Nutritional) — Essential Intracellular Divalent Cation (Cofactor for >300 ATP-De
- [10.11] Vitamin C (Ascorbic Acid) — Water-Soluble Antioxidant Vitamin & Reducing Cofactor (Prolyl/Lys